- Home
- ORMP vs ADAG Comparison
ORMP vs ADAG Comparison
Compare ORMP & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORMP
- ADAG
- Stock Information
- Founded
- ORMP 2002
- ADAG 2011
- Country
- ORMP United States
- ADAG China
- Employees
- ORMP N/A
- ADAG N/A
- Industry
- ORMP Biotechnology: Pharmaceutical Preparations
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- ORMP Health Care
- ADAG Health Care
- Exchange
- ORMP Nasdaq
- ADAG Nasdaq
- Market Cap
- ORMP N/A
- ADAG 91.4M
- IPO Year
- ORMP N/A
- ADAG 2021
- Fundamental
- Price
- ORMP $2.16
- ADAG $1.95
- Analyst Decision
- ORMP Hold
- ADAG Strong Buy
- Analyst Count
- ORMP 1
- ADAG 1
- Target Price
- ORMP N/A
- ADAG $8.00
- AVG Volume (30 Days)
- ORMP 77.2K
- ADAG 87.7K
- Earning Date
- ORMP 08-15-2025
- ADAG 07-24-2025
- Dividend Yield
- ORMP N/A
- ADAG N/A
- EPS Growth
- ORMP N/A
- ADAG N/A
- EPS
- ORMP N/A
- ADAG N/A
- Revenue
- ORMP $2,000,000.00
- ADAG $103,204.00
- Revenue This Year
- ORMP N/A
- ADAG $6,488.89
- Revenue Next Year
- ORMP N/A
- ADAG $57.50
- P/E Ratio
- ORMP N/A
- ADAG N/A
- Revenue Growth
- ORMP 196.74
- ADAG N/A
- 52 Week Low
- ORMP $1.82
- ADAG $1.33
- 52 Week High
- ORMP $3.09
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- ORMP 48.10
- ADAG 53.92
- Support Level
- ORMP $2.10
- ADAG $1.74
- Resistance Level
- ORMP $2.25
- ADAG $1.99
- Average True Range (ATR)
- ORMP 0.08
- ADAG 0.11
- MACD
- ORMP 0.00
- ADAG -0.01
- Stochastic Oscillator
- ORMP 52.63
- ADAG 58.33
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.